3-methyl-2-[(6-methylpyridin-2-yl)carbamoyl]benzoic acid | 1529805-46-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-methyl-2-[(6-methylpyridin-2-yl)carbamoyl]benzoic acid
• 英文别名: 3-Methyl-2-[(6-methylpyridin-2-yl)carbamoyl]benzoic acid
• CAS: 1529805-46-6
• 化学式: C₁₅H₁₄N₂O₃
• 分子量: 270.288
• InChiKey: MUUAPDNSQIBYPT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  79.3
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  在 lithium hydroxide 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 1.0h， 生成 3-methyl-2-[(6-methylpyridin-2-yl)carbamoyl]benzoic acid 、 2-methyl-6-[(6-methylpyridin-2-yl)carbamoyl]benzoic acid
  参考文献：
  名称：

  The identification of AF38469: An orally bioavailable inhibitor of the VPS10P family sorting receptor Sortilin

  摘要：

  The identification of the novel, selective, orally bioavailable Sortilin inhibitor AF38469 is described. Structure-activity relationships and syntheses are reported, along with an X-ray crystal structure of the sortilin-AF38469 protein-inhibitor complex.

  DOI：

  10.1016/j.bmcl.2013.11.046

文献信息

• SORTILIN ANTAGONISTS FOR USE INTHE TREATMENT OF DIABETIC RETINOPATHY
  申请人：Insusense ApS

  公开号：EP3881840A1

  公开（公告）日：2021-09-22

  The present invention relates to the use of sortilin antagonists, in particular compounds of Formula (I) and preferably Formula (II), in the treatment or prevention of diabetic retinopathy. Also provided are pharmaceutical compositions comprising the sortilin antagonists herein disclosed and methods for the treatment or prevention of diabetic retinopathy in a subject in need thereof.

  本发明涉及索司替林拮抗剂，特别是式(I)，优选式(II)化合物在治疗或预防糖尿病视网膜病变中的用途。本发明还提供了包含本发明所公开的索氏林拮抗剂的药物组合物，以及用于治疗或预防糖尿病视网膜病变的方法。
• A SORTILIN ANTAGONIST FOR USE IN THE PREVENTION OR TREATMENT OF HEARING LOSS.
  申请人：Insusense ApS

  公开号：EP3981394A1

  公开（公告）日：2022-04-13

  The present invention relates to the use of sortilin antagonists, in particular compounds of Formula (I), (II), (III), and (IV), in the treatment or prevention of hearing loss. Also provided are pharmaceutical compositions comprising the sortilin antagonists herein disclosed and methods for the treatment or prevention of hearing loss in a subject in need thereof.

  本发明涉及索西林拮抗剂，特别是式(I)、(II)、(III)和(IV)化合物在治疗或预防听力损失中的用途。本发明还提供了包含本发明公开的索替林拮抗剂的药物组合物，以及治疗或预防有需要的受试者听力损失的方法。
• [EN] SORTILIN ANTAGONISTS FOR USE IN THE TREATMENT OF DIABETIC RETINOPATHY<br/>[FR] ANTAGONISTES DE LA SORTILINE POUR DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DE LA RÉTINOPATHIE DIABÉTIQUE
  申请人：INSUSENSE APS

  公开号：WO2021186054A1

  公开（公告）日：2021-09-23

  The present invention relates to the use of sortilin antagonists, in particular compounds of Formula (I) and preferably Formula (II), in the treatment or prevention of diabetic retinopathy. Also provided are pharmaceutical compositions comprising the sortilin antagonists herein disclosed and methods for the treatment or prevention of diabetic retinopathy in a subject in need thereof.
• The identification of AF38469: An orally bioavailable inhibitor of the VPS10P family sorting receptor Sortilin
  作者：Tenna Juul Schrøder、Søren Christensen、Samsa Lindberg、Morten Langgård、Laurent David、Philip J. Maltas、Jørgen Eskildsen、Jan Jacobsen、Lena Tagmose、Klaus Bæk Simonsen、Lars Christian Biilmann Rønn、Inge E.M. de Jong、Ibrahim J. Malik、Jens-Jakob Karlsson、Christoffer Bundgaard、Jan Egebjerg、Jeffrey B. Stavenhagen、Dorthe Strandbygård、Søren Thirup、Jacob Lauwring Andersen、Srinivas Uppalanchi、Sridhar Pervaram、Shiva Prasad Kasturi、Pradheep Eradi、Durga Rao Sakumudi、Stephen P. Watson

  DOI：10.1016/j.bmcl.2013.11.046

  日期：2014.1

  The identification of the novel, selective, orally bioavailable Sortilin inhibitor AF38469 is described. Structure-activity relationships and syntheses are reported, along with an X-ray crystal structure of the sortilin-AF38469 protein-inhibitor complex.